NCT02923557.

Trial name or title	Prophylactic intravesical chemotherapy to prevent bladder cancer recurrence after nephroureterectomy for primary upper tract urothelial carcinoma patients
Methods	Single‐blinded randomised parallel group phase II study
Participants	Estimated enrollment: 200 participants Inclusion Criteria Suspected UTUC patients without history of bladder tumour Suspected UTUC patients without synchronous bladder tumour Suspected UTUC patients without contralateral UTUCs Exclusion Criteria Patients with history of bladder tumour Patients with synchronous bladder tumour Patients with contralateral UTUCs Patients with advanced stage (T4) Patients with other malignant tumours
Interventions	Group A No Intervention; blank control, do not use prophylactic intravesical chemotherapy Group B Single immediate intravesical dose of THP intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy
Outcomes	Primary outcomes Intravesical recurrence‐free survival (time to measure: three years after surgery) Secondary outcomes Cancer‐specific survival (time to measure: three years after surgery)
Starting date	November 2016; Expected date of completion: November 2021
Contact information	Xuesong Li, Associated Professor, Peking University First Hospital
Notes	Funding source: Not available